Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities-Reference-Cited by-同舟云学术

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Published:2013-06-13 Issue:24 Volume:121 Page:4867-4874
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Jain Preetesh¹,Kantarjian Hagop¹,Nazha Aziz¹,O’Brien Susan¹,Jabbour Elias¹,Romo Carlos Guillermo¹,Pierce Sherry¹,Cardenas-Turanzas Marylou¹,Verstovsek Srdan¹,Borthakur Gautam¹,Ravandi Farhad¹,Quintás-Cardama Alfonso¹,Cortes Jorge¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Key Points This analysis demonstrates the universality of the early response in CML, regardless of the treatment modality used. Factors correlating with poor cytogenetic responses at 3-mo assessment in a multivariate analysis across all 4 TKIs.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/24/4867/1366158/4867.pdf

Reference38 articles.

1. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.;Apperley;Lancet Oncol,2007

2. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.;von Bubnoff;Lancet,2002

3. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.;Saglio;N Engl J Med,2010

4. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.;Larson;Leukemia,2012

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: ELEGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI IN THE EXPERIENCE OF THE GIMEMA LABNET CML NATIONAL NETWORK;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring;American Journal of Hematology;2024-08-02

3. Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials;Leukemia Research;2024-08

4. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

5. 18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China;Frontiers in Medicine;2023-11-16